Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Fordyce also recently made the following trade(s):
- On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00.
- On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00.
- On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.
Vera Therapeutics Trading Up 0.0%
VERA traded up $0.02 during trading on Thursday, reaching $42.45. 2,339,102 shares of the company’s stock were exchanged, compared to its average volume of 1,334,068. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a one year low of $19.07 and a one year high of $56.05. The firm has a fifty day moving average price of $36.40 and a two-hundred day moving average price of $41.16. The stock has a market capitalization of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. HC Wainwright lifted their target price on Vera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday. Wedbush raised their price objective on Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research report on Wednesday. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America increased their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research report on Wednesday. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $84.58.
Get Our Latest Stock Analysis on VERA
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG increased its holdings in Vera Therapeutics by 27.9% in the fourth quarter. UBS Group AG now owns 207,289 shares of the company’s stock worth $10,497,000 after purchasing an additional 45,214 shares in the last quarter. Hudson Bay Capital Management LP boosted its holdings in shares of Vera Therapeutics by 47.4% during the 3rd quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock worth $12,804,000 after buying an additional 141,615 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares during the period. Schroder Investment Management Group increased its stake in shares of Vera Therapeutics by 82.4% in the 3rd quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock valued at $19,652,000 after acquiring an additional 307,243 shares in the last quarter. Finally, Braidwell LP acquired a new position in shares of Vera Therapeutics during the 3rd quarter valued at $13,738,000. 99.21% of the stock is owned by institutional investors and hedge funds.
Vera Therapeutics Company Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
